Stock Events

Stock Events

OncoCyte 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.27
-0.21
-0.16
-0.1
Expected EPS
-0.19996384
Actual EPS
N/A

Financials

-1,198.55%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.61MRevenue
-43.24MNet Income

Analyst Ratings

6.45Average Price Target
The highest estimate is 6.83.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7OC.STU. It's not an investment recommendation.
LENZ Therapeutics
2
LENZ
Neuronetics
2
STIM

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.67B
Fulgent Genetics
FLGT
Mkt Cap539.57M
Fulgent Genetics offers comprehensive genetic testing, including for cancer, competing in the genetic testing market.
Bionano Genomics
BNGO
Mkt Cap13.78M
Bionano Genomics provides genomic analysis solutions, competing in the genetic diagnostics space relevant to oncology.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences offers sequencing solutions that can be used in cancer research and diagnostics, competing in the genomic analysis market.
Illumina
ILMN
Mkt Cap32.55B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics and diagnostics field.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics engages in gene editing, which has applications in cancer treatment and diagnostics, presenting an indirect competition.
Natera
NTRA
Mkt Cap47.03B
Natera offers genetic testing, including for cancer, competing in the personalized medicine and diagnostics market.

About

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Show more...
CEO
Joshua Riggs
Employees
58
Country
United States
ISIN
US68235C1071
WKN
000A3EQV9

Listings

XNAS
US
IMDX
STU
DE
7OC0.STU
MU
DE
7OC0.MU
STU
DE
7OC.STU

0 Comments

Share your thoughts

FAQ

What is OncoCyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange OncoCyte stocks are traded under the ticker 7OC.STU.
When is the next OncoCyte earnings date?▼
OncoCyte is going to release the next earnings report on November 05, 2026.
What were OncoCyte earnings last quarter?▼
7OC.STU earnings for the last quarter are -0.27 EUR per share, whereas the estimation was -0.22 EUR resulting in a -22.07% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is OncoCyte revenue for the last year?▼
OncoCyte revenue for the last year amounts to 3.61M EUR.
What is OncoCyte net income for the last year?▼
7OC.STU net income for the last year is -43.24M EUR.
How many employees does OncoCyte have?▼
As of September 05, 2026, the company has 58 employees.
In which sector is OncoCyte located?▼
OncoCyte operates in the Health & Wellness sector.
When did OncoCyte complete a stock split?▼
The last stock split for OncoCyte was on July 25, 2023 with a ratio of 1:20.
Where is OncoCyte headquartered?▼
OncoCyte is headquartered in NASHVILLE, United States.